Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD11B1 | P28845 | 3/20 | 0.45 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.43 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | PDE2A | O00408 | 8/20 | 0.39 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.36 |
| ▸ | UGCG | Q16739 | 2/20 | 0.36 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2024943 | 0.88 | HSD11B1 (0.44) | HSD11B1PIK3CGTHRBPDE2AHCRTR1 | |
| SCHEMBL2019483 | 0.88 | HSD11B1 (0.44) | HSD11B1PIK3CGTHRBPDE2AHCRTR1 | |
| SCHEMBL8272799 | 0.85 | HSD11B1 (0.42) | HSD11B1PIK3CGTHRBPDE2AHCRTR1 | |
| SCHEMBL2027111 | 0.78 | HSD11B1 (0.44) | HSD11B1PIK3CGTHRBPDE2AHCRTR1 | |
| SCHEMBL13613663 | 0.76 | GRM2 (0.56) | HCRTR1HCRTR2GRM2 | |
| SCHEMBL13628484 | 0.76 | HSD11B1 (0.41) | HSD11B1PIK3CGTHRBOPRM1 | |
| SCHEMBL2019136 | 0.75 | PIK3CG (0.50) | HSD11B1PIK3CGTHRB | |
| SCHEMBL12441821 | 0.75 | PIK3CG (0.50) | HSD11B1PIK3CGTHRB | |
| SCHEMBL2023945 | 0.75 | PIK3CG (0.50) | HSD11B1PIK3CGTHRB | |
| SCHEMBL8272063 | 0.73 | UGCG (0.37) | HSD11B1PIK3CGUGCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | ASTRAZENECA AB (SE) | 2009-11-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090275578-A1 | Isoindolone compounds and their use as metabotropic glutamate receptor potentiators | GRM1, GRIN1, GRM3 | HSD11B1 492/4885PIK3CG 1735/4885THRB 524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.